Sleeve gastrostomy is known as a primary bariatric procedure for weight loss. It is a restrictive technique that led to changes in gastrointestinal transit, hormonal changes and improves in comorbidities.
Bariatric surgery is very effective at achieving sustained weight loss. It improves the control and resolution of obesity-related co-morbidities. Most studies that have demonstrated co-morbidity resolution in patients undergoing laparoscopic sleeve gastrostomy only follow patients in the short term or follow a relatively small cohort in the medium or long term.
If we focus on control of T2 DM we have the same problem. There are a lot of studies that compare Sleeve gastrostomy vs Gastric bypass assessing HbA1c, blood glucose values, change in diabetes medications or T2DM remission rates. But most of them have limitations related to the length of follow-up, use of different definitions of remission, duration and type of treatment provided, besides the fact that many are retrospective studies.
Ricard Corcelles Codina of the Hospital Clínic of Barcelona presents a review of the published literature so far and the results of our hospital, which has a high degree of specialization in bariatric surgery as well as extensive experience in the field.
The sleeve gastrostomy is a popular bariatric procedure among the surgical community. At the beginning of this century, the sleeve gastrostomy emerged as a new bariatric surgery. It was initially conceived as the first 2-stage approach to duodenal switch. It has promising short-term weight loss outcomes and amelioration of obesity related comorbidities at comparable rates to gastric bypass.